Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Different expression of lincRNAs between wild type and oxaliplatin resistant HepG2 cell line

ABSTRACT: Different expression of lincRNAs between wild type and oxaliplatin resistant HepG2 cell line

PROVIDER: PRJNA674578 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12979094.fastq.gz	Fastqsanger.gz
	SRR12979095.fastq.gz	Fastqsanger.gz
	SRR12979096.fastq.gz	Fastqsanger.gz
	SRR12979097.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Different expression of lincRNAs between wild type and oxaliplatin resistant HepG2 cell line

Project description:We found that there were 2109 differentially expressed lincRNAs between oxaliplatin resistant and wild type HCC cells, of which 1109 were up-regulated lincRNAs and 1000 were down-regulated lincRNAs.

2022-11-03 | GSE160812 | GEO

Differentially expressed genes between oxaliplatin-resistant and oxaliplatin-non-resistant patient samples [Clinical samples-RNA-seq]

Project description:To identify key drivers of oxaliplatin resistance, we collected and analyzed the DEGs between oxaliplatin-resistant and oxaliplatin-non-resistant patient samples

2023-02-28 | GSE206501 | GEO

Effect of CRISPR/Cas9 activating library on oxaliplatin resistance during oxaliplatin treatment of HepG2 cells [CRISPR cas9]

Project description:To identify key drivers of oxaliplatin, Cas9 protein was overexpressed in HepG2 cells. Next, we treated the cell pool with vehicle or OXA for 3 days to enable positive and negative screening

2023-02-28 | GSE206500 | GEO

Oxaliplatin mutational signature

Project description:Oxaliplatin mutational signature in HepG2 and MCF10A

| PRJEB30309 | ENA

Effect of CRISPR/Cas9 activating library on oxaliplatin resistance during oxaliplatin treatment of HepG2 cells [CRISPR cas9]

Project description:Effect of CRISPR/Cas9 activating library on oxaliplatin resistance during oxaliplatin treatment of HepG2 cells [CRISPR cas9]

| PRJNA851085 | ENA

Differential ncRNAs of oxaliplatin-resistant versus parental HCT116 cells

Project description:Oxaliplatin resistance frequently leads to therapeutic failure in colorectal cancer (CRC). Increasing evidence has shown that noncoding RNAs (ncRNAs) play pivotal roles in chemoresistance of CRC. However, the roles and mechanisms of ncRNAs in oxaliplatin resistance are not well understood. In this study, to identify the ncRNAs induced by oxaliplatin, we profile the expression of ncRNAs in oxaliplatin-resistant HCT116 CRC cells (HCT116oxR) and parental HCT116 cells using next-generation sequencing technology.

2023-08-31 | GSE119603 | GEO

Difference of gene expression among DLD1, oxaliplatin resistant clones derived from DLD1, HCT116, and oxaliplatin resistant clones derived from HCT116

Project description:Gene expression between DLD1 and DLD1 derived oxaliplatin resistant clones (DLD/OHP1, DLD/OHP4, and DLD/OHP5) was assessed Gene expression between HCT116 and HCT116 derived oxaliplatin resistant clones (HCT/OHP1, HCT/OHP3, and HCT/OHP5) was assessed

2020-05-31 | GSE77932 | GEO

Differentially expressed genes between oxaliplatin-resistant and oxaliplatin-non-resistant patient samples [Clinical samples-RNA-seq]

Project description:Differentially expressed genes between oxaliplatin-resistant and oxaliplatin-non-resistant patient samples [Clinical samples-RNA-seq]

| PRJNA851088 | ENA

Gene expression in xenograft tumors derived from HCT116 and its oxaliplatin resistant clones

Project description:To explore the mechanisms associated with oxaliplatin resistance, we compared gene expression in xenograft tumors derived from human colorectal cancer tumor cells HCT116 and its oxaliplatin resistant clones (HCT/OHP1 and HCT/OHP5).

2020-05-31 | GSE124808 | GEO

Differential Gene Expression in oxaliplatin-resistant versus unteated PANC1 cells

Project description:We sought to examine changes in gene expression of PANC1 cells with acquired resistance to oxaliplatin chemotherapy. Cultures of PANC1 cells, an established pancreatic cancer cell line, were exposed to oxaliplatin chemotherapy over multiple passages and acquired a stable drug-resistant phenotype labeled as PANC1OR. Previously reported immunofluorescence and western blots indicate that PANC1OR exhibit increased EMT (increased cytoskeletal vimentin, decreased E-cadherin and fibroblast-like morphology). Here we sought to examine more broadly the differential expression of genes associated with acquired drug resistance in these cells.

2024-12-19 | GSE279527 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data